Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial.
- 2025-11-03
- RCT
- The Journal of clinical endocrinology and metabolism 111(5)
- Trupti N Prasad
- Rimesh Pal
- Sanjay K Bhadada
- Sant Ram
- Veenu Singla
- Seema Pulami
- PubMed: 41183496
- DOI: 10.1210/clinem/dgaf589
- High evidence
- Clinical
Zoledronate improved only tibial total vBMD. Teriparatide significantly improved total and trabecular volumetric BMD...
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- standard of care (calcium/cholecalciferol) – specific dose not stated